U.S. Emerging Ovarian Cancer Therapeutics Market
U.S. Emerging Ovarian Cancer Therapeutics Market
RELEASE DATE
25-Jan-2002
25-Jan-2002
REGION
North America
North America
Research Code: A129-01-00-00-00
SKU: HC00814-NA-MR_04500
$2,450.00
In stock
SKU
HC00814-NA-MR_04500
Description
This report gives detailed information about market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to disease stage, namely localized-, metastatic- and relapsed/refractory disease. Key market and technology trends are discussed relative to the future of the market.
Table of Contents
Executive Summary
- Executive Summary
Overview
- Scope And Segmentation
- Epidemiology And Etiology
- Clinical Staging
- Symptoms and Diagnosis
- Treatment and Survival
- Market And Technology Trends
Market Dynamics
- Challenges
- Drivers
- Restraints
Strategic Recommendations
- Strategies Overview
- Strategic Recommendations For Market Challenge 1
- Strategic Recommendations For Market Challenge 2
- Strategic Recommendations For Market Challenge 3
- Strategic Recommendations For Market Challenge 4
- Strategic Recommendations For Market Challenge 5
Frost And Sullivan Market Engineering Awards
- Technology Innovation Award: Targeted Genetics Corporation
- Strategic Alliance Innovation Award: Supergen Corporation
- Technology Leadership Award: AltaRex Corporation
- Merger And Acquisition Strategy Award: Alza Corporation
- Business Development Strategy Award: MGI Pharma
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
Overview
Forecasts and Trends
Competitive Analysis
This report gives detailed information about market participants, revenue forecasts, market shares, projected prevalence of disease and therapeutic options, according to disease stage, namely localized-, metastatic- and relapsed/refractory disease. Key market and technology trends are discussed relative to the future of the market.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | A129-01-00-00-00 |
Is Prebook | No |